Abstract
In the past few years accumulating evidence involved chromosomal instability and the subsequent aneuploidy that it generates in tumor formation. Moreover, the misregulation of most of the proteins involved in the mitotic checkpoint as well as kinetochore assembly has proven to have tumorigenic potential in vivo. Thus, the overexpression of Ndc80/Hec1, an outer kinetochore protein involved in spindle assembly checkpoint (SAC) recruitment, has been shown to induce tumor formation in different organs. Since Ndc80/Hec1 is a protein “ highly expressed in cancer” , it is an attractive target that can be used for cancer therapy. In this direction, several strategies aiming to in vivo block this complex structure and activity are being developed, and some of them have demonstrated to have tumor growth inhibition potential. These therapies represent a potential interesting approach for the treatment of malignancies where Ndc80/Hec1 expression is upregulated. Here we will discuss different aspects of Ndc80/Hec1 biology, its role in kinetochore assembly and spindle checkpoint, and its importance as a potential therapeutical target.
Keywords: Ndc80, Hec1, Kinetochores, spindle checkpoint, aneuploidy, cancer
Current Drug Therapy
Title: Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex
Volume: 5 Issue: 1
Author(s): Elena Diaz-Rodriguez
Affiliation:
Keywords: Ndc80, Hec1, Kinetochores, spindle checkpoint, aneuploidy, cancer
Abstract: In the past few years accumulating evidence involved chromosomal instability and the subsequent aneuploidy that it generates in tumor formation. Moreover, the misregulation of most of the proteins involved in the mitotic checkpoint as well as kinetochore assembly has proven to have tumorigenic potential in vivo. Thus, the overexpression of Ndc80/Hec1, an outer kinetochore protein involved in spindle assembly checkpoint (SAC) recruitment, has been shown to induce tumor formation in different organs. Since Ndc80/Hec1 is a protein “ highly expressed in cancer” , it is an attractive target that can be used for cancer therapy. In this direction, several strategies aiming to in vivo block this complex structure and activity are being developed, and some of them have demonstrated to have tumor growth inhibition potential. These therapies represent a potential interesting approach for the treatment of malignancies where Ndc80/Hec1 expression is upregulated. Here we will discuss different aspects of Ndc80/Hec1 biology, its role in kinetochore assembly and spindle checkpoint, and its importance as a potential therapeutical target.
Export Options
About this article
Cite this article as:
Diaz-Rodriguez Elena, Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010029
DOI https://dx.doi.org/10.2174/1574885511005010029 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis
Current Molecular Medicine DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry The Effect of Claudin-5 Overexpression on the Interactions of Claudin-1 and -2 and Barrier Function in Retinal Cells
Current Molecular Medicine Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy Altering the Sphingosine-1-Phosphate/Ceramide Balance: A Promising Approach for Tumor Therapy
Current Pharmaceutical Design Interactions Between Cholinergic and Fibroblast Growth Factor Receptors in Brain Trophism and Plasticity
Current Protein & Peptide Science Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Vascular Inflammation and Atherosclerosis: The Role of Estrogen Receptors
Current Medicinal Chemistry Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Protein Kinase C Inhibitors in the Treatment of Diabetic Retinopathy. Review
Current Pharmaceutical Biotechnology Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology A Novel Relationship for Schizophrenia, Bipolar and Major Depressive Disorder Part 6: A Hint from Chromosome 6 High Density Association Screen
Current Molecular Medicine The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy Role of Androgen Receptor in Prostate Cancer Cell Cycle Regulation: Interaction with Cell Cycle Regulatory Proteins and Enzymes of DNA Synthesis
Current Protein & Peptide Science Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design